newsfilter
← Latest News
GlobeNewswire·

Braveheart Bio to Participate in the Jefferies Global Healthcare Conference in London

  • Braveheart Bio, Inc. (NASDAQ: BRVE) will participate in the Jefferies Global Healthcare Conference in London from November 16-19, 2026.
  • Management will hold a fireside chat on Wednesday, November 18, 2026, at 1:30 p.m. GMT / 8:30 a.m. ET.
  • A live webcast of the event will be available via the News & Events section of the company's website, with a replay archive provided afterward.
  • Braveheart Bio is a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) & other cardiovascular diseases.
  • The company's lead candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor (CMI) designed for obstructive HCM (oHCM) & non-obstructive HCM (nHCM).
  • BHB-1893 aims to address limitations of existing CMIs by offering rapid onset, consistent response depth, preserved systolic function, prompt reversibility, & simplified titration.